Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelm
The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefit and serious safety risks.
Call for more information
888-531-0245
info@siii-clinical.com
From research laboratories to clinical settings, SIII integrates the technologies, resources, and expertise our customers need to rise to the next opportunity. SIII is dedicated to exploring and researching the processes and scientific mechanisms underlying the world we live in.